Nafarelin
GnRH Agonist (intranasal)Also known as: Synarel
A GnRH agonist administered as a nasal spray, approved for endometriosis & central precocious puberty.
Typical Dose
200 mcg/nostril 2x/day (endometriosis); 400 mcg/nostril 2x/day (precocious puberty)
Route
Intranasal spray
Cycle
6 months (endometriosis)
Half-life
~3 hours
Storage
Room temperature, upright.
Overview
Nafarelin is a GnRH agonist available only as an intranasal spray (Synarel). It is FDA approved for endometriosis & central precocious puberty. The nasal route distinguishes it from most other GnRH agonists that require injection.
Quick Start Guide
Clinical use only. Administered as intranasal spray per prescribing information.
Research Indications
Endometriosis
Most EffectiveFDA approved. Reduces endometrial lesions & pain via estrogen suppression.
Central precocious puberty
Most EffectiveFDA approved. Suppresses premature pubertal progression.
Research Protocols
Endometriosis
6 monthsDose
200 mcg/nostril 2x/day
Frequency
Twice daily
Route
Intranasal
Side Effects & Safety
Common
- Hot flashes
- Decreased libido
- Headache
- Emotional lability
Uncommon
- Bone density loss (6-month use)
- Nasal irritation
When to Stop
- Osteoporosis risk exceeds benefit
- Signs of allergic reaction
How to Reconstitute
Pre-filled nasal spray — no reconstitution required.
Dosing math: Commercial product only.
Quality Indicators
Good — use as normal
- Per manufacturer
Discard immediately
- Discolored or crystallized solution
What to Expect
Week 2–6
Estrogen suppression & symptom reduction begin. Bone mineral density monitoring recommended for 6-month courses.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample